- Home
- VEL vs ACRS Comparison
VEL vs ACRS Comparison
Compare VEL & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | ACRS |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 765.5M | 868.5M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VEL | ACRS |
|---|---|---|
| Price | $18.19 | $6.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $22.00 | $10.20 |
| AVG Volume (30 Days) | 103.3K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.98 | ★ 69.01 |
| EPS | ★ 1.21 | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $6.01 | N/A |
| Revenue Next Year | $19.02 | $4.24 |
| P/E Ratio | $14.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.65 | $1.74 |
| 52 Week High | $21.40 | $6.60 |
Technical Indicators
Market Signals| Indicator | VEL | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 56.09 | 57.19 |
| Support Level | $17.77 | $5.64 |
| Resistance Level | $19.15 | $6.56 |
| Average True Range (ATR) | 0.39 | 0.29 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 48.54 | 61.76 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. Company operates in a large fragmented market with substantial demand for financing and limited supply of institutional financing alternative The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.